Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive two-year follow-up data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Results were shared in an oral presentation on Sunday, May 18 at the 2025 Peripheral Nerve Society (PNS) Annual Meeting in Edinburgh, United Kingdom. The Phase 3 MAGNITUDE-2 trial design of nex-z in ATTRv-PN was also exhibited in a poster presentation.
'We are pleased to share new findings at PNS, which continue to support our growing body of evidence that a single dose of nex-z leads to deep, durable and consistent reductions in serum TTRs, with evidence of disease stability or clinically meaningful improvements in neuropathic impairment measures through two years,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'These data are also the first to show improvement in patients who had previously progressed on patisiran, further validating the hypothesis that increasingly deep reductions in TTR levels may lead to improved outcomes in ATTR amyloidosis.'
ATTRv-PN Results
* Data cutoff April 11, 2025; ** Data cutoff August 21, 2024; *** Data cutoff April 12, 2024; † N=6; ‡ 24-month data in 19 patients; N/A: Data not available at Month 24
Negative change reflects improvement in the following results: NIS, mNIS+7, Norfolk QoL-DN and NfL
Positive change reflects improvement in mBMI
Study is ongoing and reported results reflect the available data as of the data cutoff
The presentation will be available on the Scientific Publications & Presentations section of intelliatx.com.
About the Nexiguran Ziclumeran (nex-z, also known as NTLA-2001) Clinical Program
The global Phase 1 trial is an ongoing open-label, multi-center, two-part study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) or transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Part 1 of the ATTRv-PN arm of the study is an open-label, single-ascending dose escalation cohort and Part 2 is an open-label, single-dose expansion cohort. Visit clinicaltrials.gov (NCT04601051) for more details.
About the MAGNITUDE-2 Study
The pivotal Phase 3 MAGNITUDE-2 clinical trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nexiguran ziclumeran (nex-z) in approximately 50 patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The primary endpoints of the study are a change in modified neuropathy impairment score and a change in serum TTR levels. Adult patients with ATTRv-PN will be randomized 1:1 to receive a single 55 mg infusion of nex-z or placebo. For more information on MAGNITUDE-2 (NCT06672237), please visit clinicaltrials.gov.
About Nex-z
Based on Nobel Prize-winning CRISPR/Cas9 gene editing technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate the TTR gene that encodes for the transthyretin (TTR) protein. Interim Phase 1 clinical data showed the administration of nex-z led to consistent, deep and long-lasting TTR reduction. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron Pharmaceuticals, Inc.
About Transthyretin (ATTR) Amyloidosis
Transthyretin amyloidosis, or ATTR amyloidosis, is a rare, progressive and fatal disease. Hereditary ATTR (ATTRv) amyloidosis occurs when a person is born with mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a propensity to misfold. These damaged proteins build up as amyloid in the body, causing serious complications in multiple tissues, including the heart, nerves and digestive system. ATTRv amyloidosis predominantly manifests as polyneuropathy (ATTRv-PN), which can lead to nerve damage, or cardiomyopathy (ATTRv-CM), which can lead to heart failure. Some individuals without the genetic mutation produce non-mutated, or wild-type TTR proteins that become unstable over time, misfolding and aggregating in disease-causing amyloid deposits. This condition, called wild-type ATTR (ATTRwt) amyloidosis, primarily affects the heart. There are an estimated 50,000 people worldwide living with ATTRv amyloidosis and between 200,000 and 500,000 people with ATTRwt amyloidosis. There is no known cure for ATTR amyloidosis and currently available medications are limited to slowing accumulation of misfolded TTR protein.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Forward-Looking Statements
This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding: the safety, tolerability, efficacy, success and advancement of its clinical programs for nexiguran ziclumeran or 'nex-z' (also known as NTLA-2001) for transthyretin ('ATTR') amyloidosis, including the ability to successfully complete its global Phase 3 MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy ('ATTRv-PN') pursuant to its clinical trial applications and investigational new drug submissions; its belief that enrollment continues to progress well in the MAGNITUDE-2 study; its belief that a single dose of nex-z leads to deep, durable and consistent reductions in serum TTR and that increasingly deep reductions in TTR levels leads to improved outcomes; and its expectation to be able to support the submission of a biologics license application for nex-z for the treatment of ATTRv-PN by 2028.
Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to enroll the Phase 3 MAGNITUDE-2 study for ATTRv-PN; the risk that any one or more of Intellia's product candidates, including nex-z, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates; and risks related to Intellia's reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
[email protected]
Media:
Matt Crenson
Ten Bridge Communications
[email protected]
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
UK economy shrunk by worse-than-expected 0.3% in April, ONS reveals, in bitter blow to Rachel Reeves
The UK economy shrank by 0.3% in April, it was revealed on Thursday, in a blow to Chancellor Rachel Reeves as her spending review comes under growing scrutiny. The latest GDP figures revealed by the Office for National Statistics is worse than the 0.1% fall expected by economists. Responding to the news, Ms Reeves acknowledged they were 'clearly disappointing' but insisted her spending review, delivered to MPs on Wednesday, would help deliver growth. The Chancellor said: 'Our number one mission is delivering growth to put more money in people's pockets through our Plan for Change, and while these numbers are clearly disappointing, I'm determined to deliver on that mission. 'In yesterday's spending review we set out how we'll deliver jobs and growth - whether that's improving city region transport, a record investment in affordable homes or funding Sizewell C nuclear power station. We're investing in Britain's renewal to make working people better off.' Speaking on Sky News, the Chancellor admitted April was a 'challenging month' but said the data was 'perhaps not entirely unexpected' given uncertainty around tariffs. Breaking news. This article is being updated.
Yahoo
36 minutes ago
- Yahoo
This Spending Review treats London as a one-way cash cow — again
The Chancellor took us on a breezy whistle-stop tour of the entire United Kingdom in her spending review statement to Parliament. Few corners of the realm were ignored as Rachel Reeves name-checked the towns and cities that will benefit from her defence, health and infrastructure spending largesse over the coming years. Lincoln, Portsmouth, Rosyth, Glasgow, Stevenage, Barrow, Derby, Blackpool and Sheffield all got a shout out as she ran MPs through some of the greatest hits of her £1.4 trillion annual sending plans. But, as has become the pattern over recent chancellor statements, there was scant mention of London, the metropolis of nine million people and economic superpower that generates much of the tax revenues she will be busily handing out over the next four years of the Parliament. The oversight did not come as a great surprise. London Labour council leaders who visited Downing Street for briefings in the run up to the spending review came away stony-faced after being told by unsmiling Treasury ministers that they were having to make 'difficult decisions' in a very tough economic environment. But without the capital firing on all cylinders, there is no hope of the UK achieving the growth that Keir Starmer and Reeves promised the nation. London is the golden goose. The oversight did not come as a great surprise Latest ONS figures showed the public sector raised £216.4bn of revenue from London taxpayers in 2023, while public spending only totalled £172.8bn in the capital. That £43.6bn annual fiscal surplus — it will be bigger this year — helps funds the spending programmes that the Chancellor outlined in her speech. By contrast, Scottish taxpayers raised just £86.8bn but £105.4bn of public money was spent north of the border, a fiscal deficit of £18.6bn. It was the same story in the north-west where tax revenues were £95.2bn, while spending totalled £130.1bn, a deficit of £34.9bn. There is nothing wrong with that. It is only right and fair that regeneration resources should be focused on those regions that have been allowed to decline so drastically since the great de-industrialisation of the Thatcher years. But London has its own acute deprivation problems too and without investment in its own housing, policing and transport infrastructure, the city will lose its status as Europe's pre-eminent metropolis, attracting the talent and capital that the UK economy depends on. Sadiq Khan promised that the election of a Labour government would lead to a new era of peaceful coexistence between City Hall and Downing Street after the scratchy years dealing with an unsympathetic Tory chancellor. But there is no disguising the disappointment from the Mayor. A glass half full view is that it could have been worse; the £2.2bn long-term funding settlement for Transport for London was better than feared. But as the Mayor laid bare in his reaction statement, 'this spending review could result in insufficient funding for the Met and fewer police officers.' He added: 'It's also disappointing that there is no commitment today from the Treasury to invest in the new infrastructure London needs. Projects such as extending the Docklands Light Railway not only deliver economic growth across the country, but also tens of thousands of new affordable homes and jobs for Londoners. Unless the Government invests in infrastructure like this in our capital, we will not be able to build the numbers of new affordable homes Londoners need.' Those are scarcely the words of the grateful recipient of bounty from his friends at the Treasury. The spending review also detailed how the machinery of government will continue to be ripped out of London and transferred to the provinces in a huge decentralisation programme. Over the next five years ministers plan to relocate 12,000 civil service roles out of the capital and 'have 50 per cent of UK-based senior civil servants in regional offices across the UK.' Sir Humphrey may have to get used to living in Harrogate rather than Hampstead. Over the same period 11 central London offices will be closed, including 102 Petty France and 39 Victoria Street. Perhaps more significant are plans to overhaul the long-standing cost-benefit rules for investment decisions that apparently have favoured London and the south-east over the rest of the country. That sends a very clear message that public investment allocations are now likely to prioritise 'levelling up' in the regions rather than maximising returns in London — at least for the next four years. So forget Crossrail 2, and do not hold out too much hope for Hammersmith Bridge ever being fixed. The anti-London tone of today's statement may make good politics. The MP for Leeds West and Pudsey will be only too aware of the existential threat posed to Labour from the Reform party forces gathering in the Red Wall towns and cities of the Midlands and the North. She needs to give those voters reasons to back Labour again in 2029 or 2030. The country can only thrive if London keeps pumping out the tax revenues While Reform is growing in strength in the capital the Government still believes it can rely on London to deliver MPs to the Labour benches at the next general election. But does it make good economics? The country can only thrive — that spending only be made, that investment only committed — if London keeps pumping out the tax revenues that pays for it. But there are worrying signs that London is feeling pressures of its own, from the flight of young families that are emptying its schools to the exodus of tech companies from the City's stock market. The alarming reality is that the Chancellor's trip round the country handing out money also certainly means she will have to ask for more tax increases in the autumn Budget. Whether that comes in the form of a further extension of income tax thresholds, which inevitably has a bigger impact in higher earning areas such as the capital, or restoring the pension lifetime allowance, as suggested by Angela Rayner, London and Londoners will bear the brunt. London has been treated as cash cow by successive chancellors ever since the financial crash. Sooner or later there will have to be some give as well as take. Sign in to access your portfolio
Wall Street Journal
38 minutes ago
- Wall Street Journal
U.K. Economy Shrinks on Tariff Hit
The U.K. economy contracted more than expected in April as the uncertainty created by President Trump's evolving trade policy brought a halt to a surprising surge in activity. Gross domestic product was 0.3% lower than a month earlier, the country's Office for National Statistics said Thursday. Economists had expected the economy to contract less sharply, by 0.1%, according to a poll compiled by The Wall Street Journal ahead of the release.
